Karyopharm Therapeutics Inc. (KPTI) financial statements (2021 and earlier)

Company profile

Business Address 85 WELLS AVENUE
NEWTON, MA 02459
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments262328146130176206156
Cash and cash equivalents129118695058151156
Short-term investments133210778011755 
Restricted cash and investments1 0    
Receivables8      
Inventory, net of allowances, customer advances and progress billings0     
Inventory0      
Other undisclosed current assets7622222
Total current assets:279335148132178208158
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment3423330
Long-term investments and receivables222945349 
Long-term investments222945349 
Restricted cash and investments110000 
Other noncurrent assets     10
Total noncurrent assets:167324938130
TOTAL ASSETS:295341180180215220158
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4237271615143
Accounts payable1465462
Accrued liabilities413221111161
Employee-related liabilities     20
Deferred revenue2
Debt2      
Deferred rent credit 0
Deferred revenue and credits220000
Other liabilities1000000
Other undisclosed current liabilities 9   (2)(0)
Total current liabilities:4647491615123
Noncurrent Liabilities
Long-term debt and lease obligation123103     
Long-term debt, excluding current maturities110103     
Operating lease, liability13
Liabilities, other than long-term debt241221 
Deferred revenue and credits1221 
Deferred revenue2
Deferred rent credit 4
Other undisclosed noncurrent liabilities745     
Total noncurrent liabilities:1991111221 
Total liabilities:245158511817143
Stockholders' equity
Stockholders' equity attributable to parent, including:50183129162198207155
Common stock0000000
Additional paid in capital923857625529455345218
Accumulated other comprehensive loss(0)(0)(0)(0)(0)(0) 
Accumulated deficit(873)(674)(495)(366)(257)(138) 
Other undisclosed stockholders' equity attributable to parent      (63)
Total stockholders' equity:50183129162198207155
TOTAL LIABILITIES AND EQUITY:295341180180215220158

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net20000
Gross profit:413020000
Operating expenses(230)(210)(132)(111)(119)(76)(34)
Operating loss:(189)(180)(131)(111)(119)(76)(34)
Nonoperating income (expense)(10)221100
Investment income, nonoperating5421100
Other nonoperating income (expense)(0)(0)(0)0(0)00
Interest and debt expense(16)(2)   (0) 
Other undisclosed income from continuing operations before equity method investments, income taxes162     
Loss from continuing operations before income taxes:(200)(178)(129)(109)(118)(76)(34)
Income tax expense (benefit)(0)(0)(0)(0) 7634
Net income (loss):(200)(178)(129)(110)(118)10
Other undisclosed net loss attributable to parent     (76) 
Net income (loss) attributable to parent:(200)(178)(129)(110)(118)(76)0
Other undisclosed net loss available to common stockholders, basic      (34)
Net loss available to common stockholders, diluted:(200)(178)(129)(110)(118)(76)(34)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(200)(178)(129)(110)(118)10
Comprehensive income (loss):(200)(178)(129)(110)(118)10
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)00(0)(76) 
Comprehensive income (loss), net of tax, attributable to parent:(199)(178)(129)(110)(118)(76)0

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: